|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recent works have studied the prognostic significance of WT1 polymorphisms and mutations, highlighting the role of SNP rs16754 as a positive prognostic factor in AML patients.
|
29407184 |
2018 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
The single-nucleotide polymorphism (SNP) within Wilms tumor-1 (WT1) exon 7, rs16754, has been arguably reported to be implicated in acute myeloid leukemia (AML) prognosis.
|
26499507 |
2016 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.
|
26644203 |
2016 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, WT1 rs16754 polymorphism is associated with better survival of AML.
|
26992216 |
2016 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
Wilms tumor gene single nucleotide polymorphism (WT1 SNP) rs16754 has been described as a favorable risk marker in patients with acute myeloid leukemia.
|
26224397 |
2015 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
The genetic variant rs16754 of Wilms tumor gene 1 (WT1) has recently been described as an independent prognostic factor in AML patients.
|
25932444 |
2015 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, WT1 rs16754 may serve as an independent biomarker in AML patients from South Chinese.
|
25841655 |
2015 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, WT1 rs16754 and WT1 expression have a significant impact on clinical outcome in patients with AML.
|
23550990 |
2014 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Wilms' tumour gene 1 (WT1) single nucleotide polymorphism (SNP) rs16754 has recently been described as an independent prognostic factor in acute myeloid leukaemia (AML) patients.
|
23484026 |
2013 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
We were unable to confirm the suggested favorable outcome of SNP rs16754 in de novo AML.
|
23070125 |
2012 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
Four-hundred and thirty-three intensively treated and molecularly characterized cytogenetically normal patients with de novo acute myeloid leukemia (18-83 years old) were analyzed for rs16754.
|
21659357 |
2011 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
The frequency of WT1 mutation in the Southeast Asian AML was thus comparable to the figures reported from the West although the designated major allele for rs16754 polymorphism was different.
|
21798259 |
2011 |
|
rs16754
|
|
Leukemia, Myelocytic, Acute
|
|
0.100 |
GeneticVariation
|
BEFREE |
To analyze the prevalence and clinical implications of Wilms' tumor 1 (WT1) single nucleotide polymorphism (SNP) rs16754 in the context of other prognostic markers in pediatric acute myeloid leukemia (AML).
|
21189390 |
2011 |